NCT05151705

A Trial of HR17031 Injection With Hepatic Insufficiency

Pharmacokinetics and Safety of HR17031 Injection in Subjects With Mild and Moderate Liver Impairment and Normal Liver Function.

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This study used a single-dose, open design to compare the pharmacokinetics of subjects with mild and moderate liver impairment and subjects with normal liver function.

Conditions

• Improved Glycemic Control in Patients With Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	HR17031 injection	Treatment group A:HR17031 injection; 10U/0.024mg
DRUG	HR17031 injection	Treatment group B: HR17031 injection; 10U/0.024mg
DRUG	HR17031 injection	Treatment group C: HR17031 injection; 10U/0.024mg

Timeline

• Start date: 2021-12-20
• Primary completion: 2022-06-15
• Completion: 2022-06-30
• First posted: 2021-12-09
• Last updated: 2021-12-09